Skip to Main Content

Paper Details

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years.
Alzheimers Dement (N Y)
34
2015
Author NameAffiliation
Rachelle S DoodyBaylor College of Medicine
Paul S AisenUniversity of California at San Diego
  • 1 - 2

Datasets

Release 1.2